Roche launches cobas MRSA/SA test to target healthcare-associated infections

Release date:2017-07-20

Published 04 July 2017

Roche has announced the CE-IVD launch of the cobas MRSA/SA nucleic acid test for use on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) at the point of care.

MRSA and SA are both major sources of healthcare and community associated infections. In fact, up to 53 million people carry MRSA, one of the most commonly identified antibiotic-resistant pathogens.1 Surveillance to manage potential MRSA/SA outbreaks has become a requirement in most healthcare facilities.

The cobas MRSA/SA test is designed to support rapid screening and surveillance of MRSA & SA – known causes of healthcare-acquired infections (HAIs), for use in emergency rooms, intensive care units and STAT lab settings. In contrast to the multiple-day turnaround needed for culture results, cobas MRSA/SA detects MRSA & SA in under 30 minutes enabling testing to occur prior to admission or surgery to reduce the risk of transmission within the hospital.

A highly sensitive and specific assay with expanded strain inclusivity, cobas MRSA/SA is the fastest CE-IVD cleared test in its class, delivering definitive results when and where they are needed most.

“The suffering and financial burden HAIs cause patients and healthcare systems demand effective surveillance for infection control and prevention,” said Roland Diggelmann, CEO Roche Diagnostics.

“The speed, performance and simplicity of the cobas MRSA/SA test provide healthcare professionals with a better chance to reduce disease proliferation as well as the opportunity to make timely patient management decisions.”

Cobas MRSA/SA is the fifth assay for use on the cobas Liat PCR System and joins cobas? Cdiff as part of the HAI portfolio. Additional assays, as part of the respiratory menu, include cobas? Strep A, cobas? Influenza A/B and cobas? Influenza A/B & RSV.

Staphylococcus aureus (SA), a gram positive bacteria and the genetically resistant form, methicillin-resistant Staphylococcus aureus (MRSA), have become the major causes of healthcare- and community-associated infections and have been responsible for bacterial outbreaks in healthcare settings worldwide.

Utilising PCR technology, the innovative cobas Liat System fully automates the testing process, simplifies workflow and enables healthcare professionals to perform molecular testing in a variety of settings with speed, reliability and minimal training. Definitive results are generated in 30 minutes or less to aid a treatment decision.

The current portfolio of assays include cobas MRSA/SA, cobas Cdiff, cobas Strep A, cobas Influenza A/B and cobas Influenza A/B & RSV. Assays for other infectious diseases are in development.

Copyright 2017 廣州藍勃生物科技有限公司版權所有 粵ICP備05081235號



快乐888电台 宁夏体彩11选5走势图 体育彩票排列5 福建11选5走势一 飞禽走兽技巧规律性 湖北十一选五选号技巧 重庆幸运农场挂机 湖北快3专家预测豹子 北京好的期货配资公司 江苏11选五走势图 腾讯分分彩在线人数开奖结果